OSLO, Norway , Sept. 8, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, is delighted to continue supporting the global launch activities of the new and improved Blue Light Cystoscopy (BLC®) system to be used with Photocure's product Hexvix® for the detection of bladder cancer. In Europe , the photodynamic diagnostics (PDD) system based on the new light source POWER LED SAPHIRA™ from KARL STORZ was featured for the first time in an E-Masterclass Webinar, hosted by both companies on September 6 . This event was accompanied by the leading experts in Urology in the field of Bladder Cancer.
Together with the experts from KARL STORZ and Photocure, Prof. Arnulf Stenzl , Prof. Lukas Lusuardi, Dr. Param Mariappan and Prof. Morgan Rouprêt showcased the new next-generation Blue Light system to the E-Masterclass participants. Over 400 registered delegates could see how the "IMAGE1 S™ SAPHIRA™" system improves visualization of bladder cancer via practical case studies. Manufactured and commercialized by KARL STORZ, the new Blue Light system is the next generation, improving the Blue Light experience and providing next-level visualization.
"In the last months, I have had the opportunity to use the new Saphira light source, which really ameliorates the quality of the procedure significantly", said Prof. Lukas Lusuardi, Professor of the Department of Urology at Paracelsus Medical University (PMU) Hospital Salzburg, Austria . "The quality of vision was exceptional – even in white light. With PDD and the new POWER LED Saphira, I was very comfortable to make the resection and TURBT under blue light, which was not the case before, I have to say. So especially with the bipolar resection, I feel quite comfortable to perform the resection under the blue light, just to be sure in the best possible way", added Prof. Morgan Rouprêt, full Professor (academic position) at APHP Sorbonne University, in the Academic Urology Department of the Pitié-Salpétrière Hospital, in Paris, France .
"We are proud to be part of the ongoing launch of this exciting new high-definition system in Europe ," commented Dr. Susanne Strauss , Vice President and General Manager, Europe at Photocure. "Photodynamic diagnostics (PDD) is an important cornerstone of accurate diagnosis and treatment of bladder cancer. This advancement in KARL STORZ's equipment will provide a better Blue Light experience for our customers, as the overwhelmingly positive feedback from the e-masterclass clearly shows," Susanne Strauss concluded.
"PDD started in Germany , with the full commitment of KARL STORZ, and so it is a pleasure for us to introduce the new IMAGE1 S™ SAPHIRA™ system in the E-Masterclass on NMIBC with PDD," said Paolo Cantù, Director Urology Global Marketing at KARL STORZ. "The new light source POWER LED SAPHIRA™ will allow us to serve the needs of our healthcare partners, providing high image quality in white light as well as in blue light for the detection and treatment of bladder cancer. Together with the Photocure team we now make high-quality BLC available to more patients worldwide".
Hexvix®/Cysview® and BLC® are registered trademarks of Photocure ASA. Saphira™ is a registered trademark of KARL STORZ Endoscopy.
This press release may contain product details and information which are not valid, or a product that is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin.
About Bladder Cancer Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1 720 000 prevalent cases (5-year prevalence rate)1a, 573 000 new cases and more than 200 000 deaths annually in 2020.1b
Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate, with up to 61% in year one and up to 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3
Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all cases and include the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3, and T4, are more likely to spread and are harder to treat.4 1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: https://gco.iarc.fr/today, accessed [January 2022 ]. 2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657 3 Sievert KD et al. World J Urol 2009;27:295–300 4 Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html
About Hexvix®/Cysview® (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada , Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in China , Chile , Australia , New Zealand and Israel . Please refer to https://photocure.com/partners/our-partners for further information on our commercial partners.
About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway , and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com
About KARL STORZ The medical technology company KARL STORZ was founded in 1945 in Tuttlingen, Germany , and is an international leader in the world of endoscopy. Now in its third generation, the family-owned company employs 8,300 people in 40 countries worldwide. The company portfolio includes more than 15,000 products for human and veterinary medicine. KARL STORZ stands for visionary design, precision craftsmanship and clinical effectiveness. Sales for the fiscal year 2021 amounted to 1.97 billion euros . Production sites are located in Germany , the USA , Switzerland and Estonia . Please find more information at: www.karlstorz.com
For further information, please contact:
Dan Schneider President and CEO Photocure ASA Email: ds@photocure.com
Erik Dahl CFO Photocure ASA Tel: +4745055000 Email: ed@photocure.com
David Moskowitz Vice President, Investor Relations Photocure ASA Tel: +1 202 280 0888 Email: david.moskowitz@photocure.com
Geir Bjørlo Corporate Communications (Norway ) Tel: +47 91540000 Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/photocure/r/bladder-cancer-technology--new-karl-storz-blue-light-cystoscopy-system-featured-during-e-masterclass,c3627628
The following files are available for download:
https://mb.cision.com/Main/17498/3627628/1624330.pdf
Immunocore Holdings plc (NASDAQ: IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types. Fifty-five patients have been treated across ten dose cohorts. IMC-F106C was well-tolerated, with treatment-related adverse events that were manageable and consistent with the mechanism of action. In the clinically active dose cohorts, durable partial responses (
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
When planning for the future, health care ranks as one of the highest concerns for both savers and retirees alike. Not only are health care costs rising by more than 5% every year, but rampant inflation and volatile market performances … Continue reading → The post New Bill May Allow Penalty-Free 401(k) Withdrawals for This Retirement Expense appeared first on SmartAsset Blog.
Shares of Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) climbed 160.4% this week, according to data from S&P Global Intelligence. The stock closed at $14.90 last Friday and then opened this Tuesday at $12.16. The stock began trading on Aug. 31 after its initial public offering (IPO).
ALBANY, N.Y. — New York declared a state of emergency on Friday to boost vaccinations against polio. Gov. Kathy Hochul issued an executive order expanding the state’s network of vaccine administrators to EMS workers, midwives and pharmacists as evidence mounts that the once rare virus is spreading in the state. Only one case of paralytic polio has been recorded in Rockland County so far, but ...
Exelixis Inc (NASDAQ: EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced renal cell carcinoma (RCC) patients. The data are being presented at the 2022 European Society of Medical Oncology (ESMO) Congress. As previously announced, the cabozantinib combination significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab. The cabozantinib combin
These strategies can help you reduce your health care costs.
Parkinson's disease (PD) may be an issue that stems from the health and function of your brain, according to the National Institute on Aging. However, a new study recently published by JAMA Network Open also reveals a connection between eating habits and mortality rates for those with PD.In a study titled "Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease," researchers took a look at 1,251 participants who were previously diagnosed with Parkin
The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.
CLAIM: A federal court order in the legal dispute over government documents held by former President Donald Trump shows President Joe Biden ordered the FBI search at Trump’s Florida home. THE FACTS: While Monday's court order from U.S. District Judge Aileen Cannon does include the phrase “as requested by the incumbent president” it’s not related to last month’s search at Mar-a-Lago. The phrase comes from a May letter from the National Archives denying Trump’s request to delay turning over documents to the FBI.
Amylyx Pharmaceuticals Inc. shares were riding high in the first few hours of trading following a key FDA advisory committee's positive vote on its first drug, despite the unusual caveats that accompanied the vote.
For a very long time, Botox was synonymous with the facial injections industry — the drug made by pharma company Allergan was approved for cosmetic use in 2002 and has since become widely used as an anti-wrinkle cosmetics treatment. Botox's dominance of the anti-wrinkle market slowly started to shift with the emergence of new products on the scene. In 2019, the Federal Drug Administration (FDA) approved the Jeuveau injectable serum made by beauty company Evolus .
Novartis AG (NYSE: NVS) has announced results from a new pooled exploratory analysis of the MONALEESA Phase 3 program of Kisqali + endocrine therapy (ET) in advanced breast cancer patients. In a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer, Kisqali + ET confirmed nearly one year of additional overall survival (OS) benefit. This subgroup analysis found that patients with visceral metas
Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.
Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.
It seems like every major technology company wants to disrupt healthcare. It's easy to see why as the United States spends nearly 18% of its gross domestic product (GDP) on healthcare. "...Because national health expenditures are projected to grow 1.1 percentage points faster than gross domestic product per year on average over 2019-28, the health share of the economy is projected to rise from 17.7% in 2018 to 19.7% in 2028."
Scott Taylor never got to move on from COVID-19. The analysis was based on data from 20 major U.S. hospital systems, including more than 1.3 million adults with a COVID diagnosis and 19,000 with a long COVID diagnosis between May 2020 and July 2022.
Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the KRYSTAL-1 Phase 1/2 study of adagrasib with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2022. In this analysis, 44 patients received adagrasib monotherapy, and 32 received the combination of adagrasib + cetuximab, with a follow-up of 20.1 months and 17.5 months, respectively. Related: Mi